Peroxisomal Dysfunction Validation in Parkinson's Disease

V2, Crosslink

🧫

Peroxisomal Dysfunction Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-peroxiso

🧫 Experiment Protocol Validationproposed

SUMMARY

# Peroxisomal Dysfunction Validation in Parkinson's Disease ## Background and Rationale This experiment addresses a critical gap in Parkinson's disease pathogenesis understanding: the role of peroxisomal dysfunction as an upstream driver of dopaminergic neurodegeneration. While mitochondrial dysfunction has dominated PD research for decades, peroxisomes—essential organelles responsible for very-long-chain fatty acid (VLCFA) metabolism, plasmalogen synthesis, and reactive oxygen species detoxific

METHODOLOGY NOTES

1. Sample Preparation: Recruit 60 PD patients (Hoehn-Yahr stages 1-3, diagnosed within 5 years) and 30 age-matched healthy controls. Collect peripheral blood mononuclear cells (PBMCs), skin fibroblasts via punch biopsy, and cerebrospinal fluid (CSF) where feasible. Generate induced pluripotent stem cells (iPSCs) from fibroblasts and differentiate into dopaminergic neurons using established protocols. 2. Experimental Groups: Study three cohorts - early PD (H&Y 1-2), moderate PD (H&Y 2-3), and controls. Additional validation using SNCA triplication patient-derived cells as positive control. 3. Peroxisomal Function Assessment: Measure VLCFA levels (C22:0, C24:0, C26:0) in plasma and cells using LC-MS/MS. Quantify plasmalogen content via targeted lipidomics. Assess peroxisomal biogenesis markers (PEX proteins) by Western blot and immunofluorescence. 4. Cellular Analyses: Evaluate peroxisome morphology and number using PMP70 immunostaining and electron microscopy. Measure catalase activity

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.902657Z'}
summary	# Peroxisomal Dysfunction Validation in Parkinson's Disease ## Background and Rationale This experiment addresses a critical gap in Parkinson's disease pathogenesis understanding: the role of peroxiso
entities	{'genes': ['VLCFA'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	validation
primary_outcome	Validate Peroxisomal Dysfunction Validation in Parkinson's Disease
methodology_notes	1. Sample Preparation: Recruit 60 PD patients (Hoehn-Yahr stages 1-3, diagnosed within 5 years) and 30 age-matched healthy controls. Collect peripheral blood mononuclear cells (PBMCs), skin fibroblast
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.902662', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

680

Outgoing

639

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Peroxisomal Dysfunction Validation in Parkinson's Disease

derives from (16)

supports (53)

💬 Discussion